Infantile polycystic kidney is mostly treated clinically with supportive therapy to avoid and control complications. However, several recent studies have shown that tolvaptan (arginine pressin V₂ receptor antagonist) can delay the increase in kidney volume and deterioration of renal function in patients with polycystic kidney, and can be used as an adjunctive treatment for autosomal dominant polycystic kidney disease to slow down the progression of the disease. 1. Control blood pressure: Hypertension is a major and controllable complication of infantile polycystic kidney, so it should be prevented. Parents should take their children to have their blood pressure monitored at least once a year. If the blood pressure exceeds the normal value, antihypertensive treatment should be started and antihypertensive drugs should be used in accordance with the doctor’s prescription. 2. Monitor proteinuria: proteinuria can reflect the progress of polycystic kidney disease and prognosis, children should also monitor proteinuria at least once a year, once proteinuria is detected, medication can be used. 3. Use acetaminophen and other drugs to reduce pain. 4. Use antibiotics to treat upper and lower urinary tract infections. 5. In recent years, tolvaptan can be used as an adjunctive treatment for autosomal dominant polycystic kidney disease to slow down the progression of the disease. If polycystic kidney continues to develop into end-stage renal disease, hemodialysis treatment or kidney transplantation is needed. For children with Polycystic Kidney Disease, parents are advised to bring their children to regular hospitals for consultation, closely observe the changes in their condition and follow the doctor’s instructions for standardized treatment.